Khosla & Leder Named 2014 Endocrine Society Visiting Professors

Sundeep Khosla, MD, and Benjamin Zev Leder, MD, have been selected as the 2014 Endocrine Society Visiting Professors in Osteoporosis and Metabolic Bone Disease. The program is supported by an educational grant from Amgen.

Khosla, a professor of medicine at the Mayo Clinic College of Medicine in Rochester, Minn., will be heading to Temple University in Philadelphia, while Leder, an associate professor of medicine at Harvard Medical School and a physician at Massachusetts General Hospital in Boston, will be on the other side of the country at the University of California, San Francisco. Both Temple and UCSF won the opportunity to host these visiting professors by applying to the program online.

“I am very thankful and honored to have been selected for the Endocrine Society’s Visiting Professor Program,” Leder says. “As an osteoporosis clinical investigator, it is especially rewarding to have been invited by the Endocrine Division at UCSF, where some of the most novel and exciting research in bone biology is underway. I hope that the exchange of ideas during my stay will in some way encourage younger faculty and fellows to continue to explore fundamental physiological questions through patient-oriented research.”

For his part, Khosla says that he is looking forward to the opportunity to talk about osteoporosis and bone biology, his area of expertise, with an engaged and interested audience. “Hopefully this will stimulate some of the faculty, particularly the junior staff, into pursuing clinical and research activities in this area,” he says, adding that he is also looking forward to learning more about the clinical and research activities ongoing at Temple. “I always find that I learn as much or more than I teach at these faculty visits.”

The Endocrine Society’s Visiting Professor Program supports visits by endocrine experts to academic institutions that demonstrate need and seeks to improve research and clinical care through meaningful educational exchanges. The program increases awareness in cutting-edge endocrine research, encourages young investigators to enter specialized endocrine research, and fosters future collaborations between investigators at different academic centers.

“It is a great honor to be selected for this program,” Khosla says. “Specifically, it is most gratifying to learn that my colleagues in endocrinology hold me in such high esteem that they would go through the competitive process to secure this award from the Endocrine Society in order to host my visit.”

Faculty at institutions that want to host a visiting professor can apply for the 2014 Visiting Professor Program in Diabetes, supported by Merck & Co., Inc., or the 2014 Visiting Professor Program in Obesity, supported by Eisai, Inc., by visiting www.endocrine.org/vpp.

— Mark A. Newman

Scott Hunt Receives AMA Medical Executive Lifetime Achievement Award

Former Endocrine Society executive director and CEO Scott Hunt was presented with the Medical Executive Lifetime Achievement Award by the American Medical Association (AMA).

The award recognizes medical executives that have made significant contributions to their organizations over the course of their tenure. As CEO Hunt was intimately involved with the Society’s strategic direction including expanding its publication base significantly, adding educational programs, advocacy, and public outreach efforts, expanding its international reach, and creating ENDOExpo. He engineered the Society’s growth to become one of Washington Business Journal’s top 50 associations.

“The Endocrine Society is incredibly grateful for the many years of visionary leadership that Scott Hunt provided,” says Richard Santen, MD, Endocrine Society president. “He is more than deserving of a lifetime achievement award, and we applaud his accomplishment.”

In 2007, the American Medical Association honored Hunt with the Medical Executive Meritorious Achievement Award. The award is given to a medical association executive who has demonstrated exceptional service and contributions to the goals and ideals of the medical profession.
Hunt retired from the Endocrine Society in 2013 after 25 years leading the organization.

Endocrine Society’s Early Investigators Awards

The Early Investigators Awards help support early career investigators continue independent research in endocrinology. Outstanding contributions will be showcased in a recognition campaign throughout the Endocrine Society community and each recipient’s hometown.

Nominees must hold an MD, PhD, or MD/PhD and be a newly appointed faculty member within 10 years from the terminal degree granting date.

View award details and submit your nomination today at www.endocrine.org/eia.

This award is supported by Endocrine Society and Pfizer, Inc. Application Deadline: December 22, 2014.

Endocrine Society’s Research Fellowship Awards

The Society’s Research Fellowship Awards recognize outstanding achievements of early career professionals and provide generous support for their research projects and career endeavors. Learn more about the following awards including eligibility criteria and submission requirements:

  • Acromegaly Clinical Research Fellowship Award, supported by Pfizer, Inc.
  • Clinical Research Fellowship Award in Women’s Health, supported by Pfizer, Inc.
  • Endocrine Scholars Award in Growth Hormone Research, supported by Genentech
  • Summer Research Fellowships, supported by the Endocrine Society

For more information, go to www.endocrine.org/awards.
Application Deadline: December 22, 2014.

You may also like

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

  • New Position Statement Focuses on Patient Experience in Diabetes Care

    Healthcare providers who treat diabetes need to think beyond the clinical numbers, such as solely focusing on a person’s glucose goals. Taking the patient experience into account can improve the quality of care and facilitate attainment of treatment goals, according to a new position statement published in the Endocrine Society’s Journal of Clinical Endocrinology &…

Find more in